606 related articles for article (PubMed ID: 8932846)
1. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
3. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
Frassoni F; Labopin M; Gluckman E; Prentice HG; Vernant JP; Zwaan F; Granena A; Gahrton G; De Witte T; Gratwohl A; Reiffers J; Gorin NC
Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048
[TBL] [Abstract][Full Text] [Related]
4. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
5. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
6. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
[TBL] [Abstract][Full Text] [Related]
7. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
[TBL] [Abstract][Full Text] [Related]
8. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
[TBL] [Abstract][Full Text] [Related]
9. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation.
Hiraoka A; Ohashi Y; Okamoto S; Moriyama Y; Nagao T; Kodera Y; Kanamaru A; Dohy H; Masaoka T;
Bone Marrow Transplant; 2001 Jul; 28(2):181-5. PubMed ID: 11509936
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.
Chao NJ; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM
N Engl J Med; 1993 Oct; 329(17):1225-30. PubMed ID: 8413388
[TBL] [Abstract][Full Text] [Related]
11. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.
Nordlander A; Mattsson J; Ringdén O; Leblanc K; Gustafsson B; Ljungman P; Svenberg P; Svennilson J; Remberger M
Biol Blood Marrow Transplant; 2004 Mar; 10(3):195-203. PubMed ID: 14993885
[TBL] [Abstract][Full Text] [Related]
12. GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants.
Olsson R; Remberger M; Hassan Z; Omazic B; Mattsson J; Ringdén O
Eur J Haematol; 2010 Apr; 84(4):323-31. PubMed ID: 20002156
[TBL] [Abstract][Full Text] [Related]
13. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
Schwinghammer TL; Bloom EJ
Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.
Carlens S; Ringdén O; Remberger M; Lönnqvist B; Hägglund H; Klaesson S; Mattsson J; Svahn BM; Winiarski J; Ljungman P; Aschan J
Bone Marrow Transplant; 1998 Oct; 22(8):755-61. PubMed ID: 9827972
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
17. Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings.
Ringdén O; Klaesson S; Sundberg B; Ljungman P; Lönnqvist B; Persson U
Bone Marrow Transplant; 1992 Jan; 9(1):19-25. PubMed ID: 1543946
[TBL] [Abstract][Full Text] [Related]
18. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
Atkinson K; Downs K
Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
[TBL] [Abstract][Full Text] [Related]
19. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ
Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants.
Hoyt R; Ritchie DS; Roberts AW; Macgregor L; Curtis DJ; Szer J; Grigg AP
Bone Marrow Transplant; 2008 Apr; 41(7):651-8. PubMed ID: 18176619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
